Drugs / CVXGA1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04954287 | Aug 2021 → Jun 2023 | COVID-19 | CyanVac LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVXGA1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04954287 ↗ |
| Route | Intranasal | “single dose of intranasal CVXGA1” NCT04954287 ↗ |